Impact of suboptimal or inappropriate treatment on healthcare resource use and cost among patients with uncomplicated urinary tract infection: an analysis of integrated delivery network electronic health records.


Journal

Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411

Informations de publication

Date de publication:
04 11 2022
Historique:
received: 08 06 2022
accepted: 17 10 2022
entrez: 5 11 2022
pubmed: 6 11 2022
medline: 9 11 2022
Statut: epublish

Résumé

Although uncomplicated urinary tract infections (uUTIs; occurring in female patients without urological abnormalities or history of urological procedures or complicating comorbidities) are one of the most common community infections in the United States (US), limited data are available concerning associations between antibiotic resistance, suboptimal prescribing, and the economic burden of uUTI. We examined the prevalence of suboptimal antibiotic prescribing and antibiotic resistance and its effects on healthcare resource use and costs. This retrospective cohort study utilized electronic health record data from a large Mid-Atlantic US integrated delivery network database, collected July 2016-March 2020. Female patients aged ≥ 12 years with a uUTI, who received ≥ 1 oral antibiotic treatment within ± 5 days of index uUTI diagnosis, and had ≥ 1 urine culture with antimicrobial susceptibility test, were eligible for inclusion in the study. The study examined the proportion of antibiotics that were inappropriately or suboptimally prescribed among patients with confirmed uUTI, and total healthcare costs (all-cause and UTI-related) within 6 months after a uUTI, stratified by antibiotic susceptibility and/or inappropriate or suboptimal treatment. Patient outcomes were assessed after 1:1 propensity score matching of patients with antibiotic-susceptible versus not-susceptible isolates and then by other covariates (e.g., demographics and recent healthcare use). A similar propensity score calculation was used to analyze the effect of inappropriate/suboptimal treatment on health outcomes. Costs were adjusted to 2020 US dollars ($). Among 2565 patients with a uUTI included in the analysis, the most commonly prescribed antibiotics were nitrofurantoin (61%), trimethoprim-sulfamethoxazole (19%), and ciprofloxacin (15%). More than one-third of the sample (40.2%) had isolates that were not-susceptible to ≥ 1 antibiotic indicated for treating patients with uUTI. Two-thirds (66.6%) of study-eligible patients were prescribed appropriate treatment; 29.9% and 11.9% were prescribed suboptimal and/or inappropriate treatment, respectively. Inappropriate or suboptimally prescribed patients had greater all-cause and UTI-related costs compared with appropriately prescribed patients. Differences were most striking among patients with antibiotic not-susceptible isolates. These findings highlight how the increasing prevalence of antibiotic resistance combined with suboptimal treatment of patients with uUTI increases the burden on healthcare systems. The finding underlines the need for improved prescribing accuracy by better understanding regional resistance rates and developing improved diagnostic tests.

Sections du résumé

BACKGROUND
Although uncomplicated urinary tract infections (uUTIs; occurring in female patients without urological abnormalities or history of urological procedures or complicating comorbidities) are one of the most common community infections in the United States (US), limited data are available concerning associations between antibiotic resistance, suboptimal prescribing, and the economic burden of uUTI. We examined the prevalence of suboptimal antibiotic prescribing and antibiotic resistance and its effects on healthcare resource use and costs.
METHODS
This retrospective cohort study utilized electronic health record data from a large Mid-Atlantic US integrated delivery network database, collected July 2016-March 2020. Female patients aged ≥ 12 years with a uUTI, who received ≥ 1 oral antibiotic treatment within ± 5 days of index uUTI diagnosis, and had ≥ 1 urine culture with antimicrobial susceptibility test, were eligible for inclusion in the study. The study examined the proportion of antibiotics that were inappropriately or suboptimally prescribed among patients with confirmed uUTI, and total healthcare costs (all-cause and UTI-related) within 6 months after a uUTI, stratified by antibiotic susceptibility and/or inappropriate or suboptimal treatment. Patient outcomes were assessed after 1:1 propensity score matching of patients with antibiotic-susceptible versus not-susceptible isolates and then by other covariates (e.g., demographics and recent healthcare use). A similar propensity score calculation was used to analyze the effect of inappropriate/suboptimal treatment on health outcomes. Costs were adjusted to 2020 US dollars ($).
RESULTS
Among 2565 patients with a uUTI included in the analysis, the most commonly prescribed antibiotics were nitrofurantoin (61%), trimethoprim-sulfamethoxazole (19%), and ciprofloxacin (15%). More than one-third of the sample (40.2%) had isolates that were not-susceptible to ≥ 1 antibiotic indicated for treating patients with uUTI. Two-thirds (66.6%) of study-eligible patients were prescribed appropriate treatment; 29.9% and 11.9% were prescribed suboptimal and/or inappropriate treatment, respectively. Inappropriate or suboptimally prescribed patients had greater all-cause and UTI-related costs compared with appropriately prescribed patients. Differences were most striking among patients with antibiotic not-susceptible isolates.
CONCLUSIONS
These findings highlight how the increasing prevalence of antibiotic resistance combined with suboptimal treatment of patients with uUTI increases the burden on healthcare systems. The finding underlines the need for improved prescribing accuracy by better understanding regional resistance rates and developing improved diagnostic tests.

Identifiants

pubmed: 36333740
doi: 10.1186/s13756-022-01170-3
pii: 10.1186/s13756-022-01170-3
pmc: PMC9636777
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

133

Informations de copyright

© 2022. The Author(s).

Références

J Antimicrob Chemother. 2006 Nov;58(5):1000-8
pubmed: 16998209
J Pediatr Pharmacol Ther. 2019 Jan-Feb;24(1):39-44
pubmed: 30837813
Antimicrob Resist Infect Control. 2022 Jun 14;11(1):84
pubmed: 35701853
Clin Infect Dis. 2021 Dec 6;73(11):1992-1999
pubmed: 34143881
Open Forum Infect Dis. 2018 Aug 10;5(9):ofy198
pubmed: 30191156
J Glob Antimicrob Resist. 2021 Sep;26:148-153
pubmed: 34118479
Clin Infect Dis. 2011 Mar 1;52(5):e103-20
pubmed: 21292654
Am Fam Physician. 2005 Aug 1;72(3):451-6
pubmed: 16100859
Infection. 2015 Feb;43(1):89-94
pubmed: 25033939
Infect Chemother. 2018 Mar;50(1):67-100
pubmed: 29637759
BMJ. 2010 May 18;340:c2096
pubmed: 20483949
Am Fam Physician. 2011 Oct 1;84(7):771-6
pubmed: 22010614
Clin Infect Dis. 2021 Nov 2;73(9):e2763-e2772
pubmed: 32590839
Eur J Clin Pharmacol. 2013 Sep;69(9):1701-7
pubmed: 23660771
Infect Control Hosp Epidemiol. 2021 Dec;42(12):1437-1444
pubmed: 33622432
J Clin Pharm Ther. 2004 Oct;29(5):437-41
pubmed: 15482387
Ther Adv Urol. 2019 May 02;11:1756287219832172
pubmed: 31105774
Br J Gen Pract. 2015 Oct;65(639):e702-7
pubmed: 26412847
J Infect. 2007 Sep;55(3):254-9
pubmed: 17574678
BMC Geriatr. 2021 Jul 23;21(1):436
pubmed: 34301192
Curr Allergy Asthma Rep. 2017 Aug;17(8):56
pubmed: 28752367
J Infect. 2015 Dec;71(6):667-74
pubmed: 26380898
Antimicrob Agents Chemother. 2012 Apr;56(4):2181-3
pubmed: 22252813
Dtsch Arztebl Int. 2011 Jun;108(24):415-23
pubmed: 21776311

Auteurs

Jason Shafrin (J)

PRECISIONheor, Los Angeles, CA, USA.

Alen Marijam (A)

GSK, Collegeville, PA, USA.

Ashish V Joshi (AV)

GSK, Collegeville, PA, USA. ashish.2.joshi@gsk.com.

Fanny S Mitrani-Gold (FS)

GSK, Collegeville, PA, USA.

Katie Everson (K)

PRECISIONheor, Austin, TX, USA.

Rifat Tuly (R)

PRECISIONheor, Los Angeles, CA, USA.

Peter Rosenquist (P)

PRECISIONheor, Washington, DC, USA.

Michael Gillam (M)

MedStar Health, Washington, DC, USA.

Maria Elena Ruiz (ME)

MedStar Health, Washington, DC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH